DalsnaFinance

Pentixapharm Holding AG: FDA grants "Study May Proceed" for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review of the 2024 Consolidated Financial Statements

Markets PR Newswire By PR Newswire 09 Jun 2026 07:06 1 min read
Pentixapharm Holding AG: FDA grants "Study May Proceed" for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review of the 2024 Consolidated Financial Statements

DISCLOSURE OF INSIDE INFORMATION PURSUANT TO ART. 17 OF REGULATION (EU) No. 596/2014 (MARKET ABUSE REGULATION) BERLIN, June 9, 2026 /PRNewswire/ -- Pentixapharm Holding AG: FDA grants "Study May Proceed" for PANDA Phase 3 Study; Intended Capital Increase with Subscription Rights in a...

DISCLOSURE OF INSIDE INFORMATION PURSUANT TO ART. 17 OF REGULATION (EU) No. 596/2014 (MARKET ABUSE REGULATION) BERLIN, June 9, 2026 /PRNewswire/ -- Pentixapharm Holding AG: FDA grants "Study May Proceed" for PANDA Phase 3 Study; Intended Capital Increase with Subscription Rights in a...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.